The United States Food and Drug Administration (FDA) has granted regulatory authorization through its De Novo pathway for the first fully autonomous robotic venipuncture and blood draw system designed for clinical healthcare environments. The medical device utilizes high-resolution near-infrared imaging, 3D ultrasound guidance, and machine learning algorithms to map vascular anatomy, identify optimal veins, and execute precise blood sample collection under physician supervision. Clinical trial data submitted to federal regulators demonstrated a 97 percent first-stick success rate, significantly reducing patient discomfort, insertion trauma, and procedural delays often associated with difficult venous access. Health system administrators emphasize that deploying automated phlebotomy infrastructure directly addresses ongoing national shortages of trained laboratory technicians while reducing needle-stick injury risks for healthcare personnel. Medical technology analysts note that introducing autonomous robotics into routine diagnostic workflows marks a foundational milestone in hospital automation, paving the way for streamlined outpatient admissions, standardized blood sampling, and reduced operational costs across emergency and primary care networks. Regulatory Milestone Establishes New Category for Autonomous PhlebotomyIn a major advancement for medical automation, the US Food and Drug Administration (FDA) granted De Novo marketing authorization for Aletta, an autonomous robotic phlebotomy device developed by Netherlands-based medical technology firm Vitestro. The regulatory decision establishes a new medical device classification in the United States, allowing a standalone robotic system to execute diagnostic blood collection directly from an adult patient's arm without manual needle manipulation by a human technician. Authorized for outpatient clinical settings, the technology addresses acute staffing shortages across healthcare networks by enabling a single trained phlebotomist to supervise up to three robotic units simultaneously. Overview: Vitestro Aletta Robotic Blood Draw System & FDA ClearanceSystem & Regulatory ParameterSpecifications & Operational GuidelinesDeveloper / ManufacturerVitestro (Utrecht, Netherlands)Regulatory PathwayFDA De Novo Authorization (Class II novel medical device)Operational TargetAdult outpatient diagnostic blood collectionImaging & Sensing SuiteNear-Infrared (NIR) light, 3D structure light, & Doppler UltrasoundSupervision Ratio1 trained phlebotomist per 3 operating Aletta unitsSafety InterlocksAuto-detaching needle mechanics, movement sensors, & automatic vein exclusionMultimodal Imaging and Autonomous End-to-End Sample CollectionThe Aletta device automates the entire venipuncture workflow once a patient inserts their arm into the system's ergonomic bay. Using a combination of near-infrared (NIR) imaging and Doppler ultrasound, the platform maps subcutaneous arm anatomy in real time, automatically differentiating suitable veins from nearby arteries and nerves. If no acceptable vein structure is detected, the device safely aborts the process. Upon identifying an optimal insertion site, the system autonomously applies a tourniquet, sterilizes the skin, inserts the needle, switches specimen collection tubes in the correct diagnostic sequence, applies pressure, and places a bandage. Clinical Efficacy, Safety Interlocks, and Operational EfficiencyThe FDA based its clearance on clinical trial data—including findings from the multicenter ADOPT study—demonstrating that Aletta achieved first-stick success rates comparable to or exceeding those of experienced human phlebotomists across diverse patient populations, including individuals with dark skin tones or self-reported difficult venous access. Built-in safety interlocks immediately detach the needle and retract the arm assembly if patient movement exceeds safety thresholds. By standardizing routine sample acquisition and mitigating needle-stick injuries among hospital personnel, the automated system offers clinical laboratories a scalable tool to streamline diagnostic workflows.